July 22nd 2024
An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.
Diabetes Dialogue: All Things AID at ATTD 2024
March 28th 2024In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.
Endocrinology Month in Review: February 2024
March 6th 2024In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.
Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial
March 5th 2024Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Diabetes Dialogue: Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
March 4th 2024In this episode, hosts are joined by SURMOUNT-2 principal investigator Timothy Garvey, MD, to discuss the approval of the tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.